Regeneus Ltd. (AU:CMB)
ASX:CMB
Want to see AU:CMB full AI Analyst Report?
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)3.93K
Market Cap
AU$10.80M
Enterprise ValueAU$9.39M
Total Cash (Recent Filing)AU$166.41K
Total Debt (Recent Filing)AU$482.71K
Price to Earnings (P/E)―
Beta-3.08
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding27,331,919
10 Day Avg. Volume7,693
30 Day Avg. Volume3,926
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.09
Price to Sales (P/S)5.73
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary IP & Focused Business ModelA clear, specialised focus on regenerative medicine with proprietary cell-based products, manufacturing capability and IP creates durable competitive barriers. This vertical integration supports commercialization pathways for musculoskeletal indications and increases long-term monetization potential if clinical milestones are met.
High Product-Level Gross MarginA ~69% gross margin indicates attractive unit economics for existing offerings. If revenue growth continues, healthy gross margins allow operating leverage to flow to the bottom line, improving margin sustainability over months as fixed R&D and manufacturing costs are absorbed by higher volumes.
Low Debt Burden / Moderate LeverageModest absolute debt and a low debt-to-equity ratio reduce near-term solvency pressure and interest costs. With limited creditor risk, management retains financial flexibility to fund clinical/commercial activity through equity or targeted financing rather than servicing large debt, supporting medium-term strategic options.
Bears Say
High Cash BurnSustained negative operating and free cash flow of this magnitude materially shortens the company’s runway absent new funding or sharp revenue gains. Persistent cash burn forces recurring capital raises, increasing dilution risk and constraining the ability to invest selectively in late-stage trials or commercialization scaling over the next several quarters.
Ongoing Losses And Weak ProfitabilityMaterial net losses and negative operating margins indicate the cost base far exceeds current revenues. Without durable revenue expansion or cost reductions, profitability is unlikely in the near term, worsening returns on invested capital and increasing dependency on external financing to sustain operations.
Small, Volatile Revenue BaseRevenue remains very small and historically volatile, limiting visibility into sustainable demand and margin scalability. A low base amplifies growth swings and makes multi-quarter forecasting unreliable, raising execution risk for commercialization and complicating sensible resource allocation decisions over coming quarters.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.19 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$10.80M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 97 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 27,331,919 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.22%
12-Months-Change
Fundamentals
Return on Equity
-218.76%
Trailing 12-Months
Asset Growth
-5.07%
Trailing 12-Months
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---